Assenagon Asset Management S.A. Acquires 547,212 Shares of Edwards Lifesciences Corporation $EW

Key Points

• Assenagon Asset Management increased its Edwards Lifesciences stake by 43.2% in the second quarter, purchasing 547,212 additional shares and bringing its holdings to 1.81 million shares worth approximately $164 million.
• Edwards reported stronger-than-expected quarterly results, with EPS of $0.78 and revenue of $1.74 billion; revenue rose 13.6% year over year. The company issued third-quarter and full-year 2026 EPS guidance.
• Wall Street maintains a generally positive view, with a “Moderate Buy” consensus and an average price target of $100.27 versus the stock’s reported price of $89.33. However, insiders sold 43,539 shares worth about $3.7 million over the past 90 days.

Assenagon Asset Management S.A. increased its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 43.2% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,812,926 shares of the medical research company's stock after buying an additional 547,212 shares during the period. Assenagon Asset Management S.A. owned about 0.31% of Edwards Lifesciences worth $163,997,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in EW. Brighton Jones LLC bought a new stake in shares of Edwards Lifesciences in the fourth quarter worth $266,000. NewEdge Advisors LLC increased its holdings in Edwards Lifesciences by 8.1% in the second quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company's stock valued at $2,787,000 after purchasing an additional 2,665 shares during the period. Sei Investments Co. raised its position in Edwards Lifesciences by 16.7% during the 2nd quarter. Sei Investments Co. now owns 412,808 shares of the medical research company's stock worth $32,285,000 after purchasing an additional 58,988 shares during the last quarter. Squarepoint Ops LLC raised its position in Edwards Lifesciences by 277.7% during the 2nd quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company's stock worth $5,417,000 after purchasing an additional 50,924 shares during the last quarter. Finally, Treasurer of the State of North Carolina lifted its holdings in Edwards Lifesciences by 0.4% during the 2nd quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company's stock worth $21,028,000 after buying an additional 1,065 shares during the period. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Stock Performance

Shares of EW opened at $89.33 on Friday. The company has a current ratio of 4.52, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $51.44 billion, a P/E ratio of 51.34, a price-to-earnings-growth ratio of 2.23 and a beta of 0.85. The firm's fifty day simple moving average is $88.13 and its two-hundred day simple moving average is $84.04. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $96.29.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.74 by $0.04. The firm had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The business's revenue was up 13.6% compared to the same quarter last year. During the same period last year, the business posted $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 619 shares of the business's stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $91.70, for a total value of $56,762.30. Following the transaction, the vice president directly owned 40,034 shares of the company's stock, valued at approximately $3,671,117.80. The trade was a 1.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total value of $2,000,190.90. Following the transaction, the vice president owned 98,611 shares in the company, valued at $8,521,962.62. The trade was a 19.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 43,539 shares of company stock valued at $3,685,364 over the last 90 days. Company insiders own 0.31% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on EW shares. Evercore reiterated an "outperform" rating and issued a $100.00 price target on shares of Edwards Lifesciences in a research report on Monday, July 6th. Mizuho raised their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 15th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Edwards Lifesciences in a research note on Friday, July 17th. Robert W. Baird lifted their price objective on Edwards Lifesciences from $85.00 to $87.00 and gave the stock a "neutral" rating in a research note on Friday, April 24th. Finally, JPMorgan Chase & Co. upped their target price on Edwards Lifesciences from $100.00 to $105.00 and gave the company an "overweight" rating in a report on Friday, July 24th. Seventeen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $100.27.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source